Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma.
Sylvia C KurzElcin ZanChristine CordovaAndrea B TroxelMarissa BarbaroJoshua S SilvermanMatija SnuderlDavid ZagzagDouglas KondziolkaJohn G GolfinosAndrew S ChiErik P SulmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Treatment with 177Lu-DOTATATE was well tolerated. The predefined PFS-6 threshold was met in this interim analysis, thereby allowing this multicenter clinical trial to continue enrollment. 68Ga-DOTATATE PET may be a useful imaging biomarker to assess therapeutic outcome in patients with meningioma.